These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 21881677)

  • 1. Integration of cell phone imaging with microchip ELISA to detect ovarian cancer HE4 biomarker in urine at the point-of-care.
    Wang S; Zhao X; Khimji I; Akbas R; Qiu W; Edwards D; Cramer DW; Ye B; Demirci U
    Lab Chip; 2011 Oct; 11(20):3411-8. PubMed ID: 21881677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microchip ELISA coupled with cell phone to detect ovarian cancer HE4 biomarker in urine.
    Wang S; Akbas R; Demirci U
    Methods Mol Biol; 2015; 1256():111-21. PubMed ID: 25626535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bead-based ELISA for validation of ovarian cancer early detection markers.
    Scholler N; Crawford M; Sato A; Drescher CW; O'Briant KC; Kiviat N; Anderson GL; Urban N
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2117-24. PubMed ID: 16609024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms.
    Hellstrom I; Heagerty PJ; Swisher EM; Liu P; Jaffar J; Agnew K; Hellstrom KE
    Cancer Lett; 2010 Oct; 296(1):43-8. PubMed ID: 20381233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
    Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
    Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting.
    Jacob F; Meier M; Caduff R; Goldstein D; Pochechueva T; Hacker N; Fink D; Heinzelmann-Schwarz V
    Gynecol Oncol; 2011 Jun; 121(3):487-91. PubMed ID: 21420727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Programmable bio-nano-chip systems for serum CA125 quantification: toward ovarian cancer diagnostics at the point-of-care.
    Raamanathan A; Simmons GW; Christodoulides N; Floriano PN; Furmaga WB; Redding SW; Lu KH; Bast RC; McDevitt JT
    Cancer Prev Res (Phila); 2012 May; 5(5):706-16. PubMed ID: 22490510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HE4 as a biomarker for ovarian and endometrial cancer management.
    Li J; Dowdy S; Tipton T; Podratz K; Lu WG; Xie X; Jiang SW
    Expert Rev Mol Diagn; 2009 Sep; 9(6):555-66. PubMed ID: 19732003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HE4: a new potential early biomarker for the recurrence of ovarian cancer.
    Anastasi E; Marchei GG; Viggiani V; Gennarini G; Frati L; Reale MG
    Tumour Biol; 2010 Apr; 31(2):113-9. PubMed ID: 20358424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer.
    Anderson KS; Wong J; Vitonis A; Crum CP; Sluss PM; Labaer J; Cramer D
    Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):859-68. PubMed ID: 20200435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm.
    Van Gorp T; Cadron I; Despierre E; Daemen A; Leunen K; Amant F; Timmerman D; De Moor B; Vergote I
    Br J Cancer; 2011 Mar; 104(5):863-70. PubMed ID: 21304524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma.
    Hellström I; Raycraft J; Hayden-Ledbetter M; Ledbetter JA; Schummer M; McIntosh M; Drescher C; Urban N; Hellström KE
    Cancer Res; 2003 Jul; 63(13):3695-700. PubMed ID: 12839961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?
    Montagnana M; Danese E; Ruzzenente O; Bresciani V; Nuzzo T; Gelati M; Salvagno GL; Franchi M; Lippi G; Guidi GC
    Clin Chem Lab Med; 2011 Mar; 49(3):521-5. PubMed ID: 21288178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125.
    Shah CA; Lowe KA; Paley P; Wallace E; Anderson GL; McIntosh MW; Andersen MR; Scholler N; Bergan LA; Thorpe JD; Urban N; Drescher CW
    Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1365-72. PubMed ID: 19423517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrence monitoring for ovarian cancer using a cell phone-integrated paper device to measure the ovarian cancer biomarker HE4/CRE ratio in urine.
    Kight EC; Hussain I; Bowden AK; Haselton FR
    Sci Rep; 2021 Nov; 11(1):21945. PubMed ID: 34754053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case-control study in a Korean population.
    Kim YM; Whang DH; Park J; Kim SH; Lee SW; Park HA; Ha M; Choi KH
    Clin Chem Lab Med; 2011 Mar; 49(3):527-34. PubMed ID: 21320028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms: Clinical correlates.
    Liao JB; Yip YY; Swisher EM; Agnew K; Hellstrom KE; Hellstrom I
    Gynecol Oncol; 2015 Jun; 137(3):430-5. PubMed ID: 25866324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic accuracy of urine HE4 in patients with ovarian cancer: a meta-analysis.
    Jia MM; Deng J; Cheng XL; Yan Z; Li QC; Xing YY; Fan DM; Tian XY
    Oncotarget; 2017 Feb; 8(6):9660-9671. PubMed ID: 28039447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses.
    Abdel-Azeez HA; Labib HA; Sharaf SM; Refai AN
    Asian Pac J Cancer Prev; 2010; 11(1):111-6. PubMed ID: 20593939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other.
    Hellstrom I; Hellstrom KE
    Adv Exp Med Biol; 2008; 622():15-21. PubMed ID: 18546615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.